Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10724044 | 0.89 | IDH1 (1.00) | IDH1 | |
| SCHEMBL14140191 | 0.89 | IDH1 (0.66) | IDH1 | |
| SCHEMBL1859786 | 0.87 | IDH1 (0.84) | IDH1 | |
| SCHEMBL9656785 | 0.84 | IDH1 (0.67) | IDH1 | |
| SCHEMBL9656734 | 0.82 | IDH1 (0.67) | IDH1 | |
| SCHEMBL9657402 | 0.82 | IDH1 (0.85) | IDH1 | |
| SCHEMBL10723992 | 0.82 | IDH1 (1.00) | IDH1 | |
| SCHEMBL10726777 | 0.81 | IDH1 (0.74) | IDH1 | |
| SCHEMBL10724140 | 0.81 | IDH1 (0.74) | IDH1 | |
| SCHEMBL9658467 | 0.80 | IDH1 (0.58) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329835-A1 | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-8227490-B2 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110269801-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | Salix Pharmaceuticals, Ltd | 2011-11-03 | — | — | US | disclosed |
| US-7981909-B2 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112153-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | BAUSCH HEALTH US, LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112150-A2 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | BOHN MANFRED | 2011-05-12 | — | — | US | disclosed |
| US-20100076031-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | BOHN MANFRED | 2010-03-25 | — | — | US | disclosed |
| EP-1049468-B1 | UTILIZATION OF POWDER PREPARATIONS CONTAINING HYDROXYPYRIDONES FOR TREATING LEG ULCERS AND DECUBITUS ULCERS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-20070071705-A1 | Topical anti-microbial compositions | STIEFEL LABORATORIES, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1499312-B1 | THE USE OF HYDROXYPYRIDONE-DERIVATIVES IN WOUND HEALING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-28 | — | — | EP | disclosed |
| EP-0928193-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SKIN DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-07-14 | — | — | EP | disclosed |
| EP-0865277-A1 | USE OF FUNGICIDAL AGENTS FOR SELECTIVE DECONTAMINATION OF TEETH AND DENTAL PROSTHESES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998013043-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SKIN DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-02 | — | — | WO | disclosed |
| CN-1156958-A | Use of glyceryl triacetate for treating onychomycoses | HOECHST AG (DE) | 1997-08-13 | — | — | CN | disclosed |
| WO-1997020559-A1 | USE OF FUNGICIDAL AGENTS FOR SELECTIVE DECONTAMINATION OF TEETH AND DENTAL PROSTHESES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-12 | — | — | WO | disclosed |
| EP-0777457-A1 | USE OF GLYCERYL TRIACETATE FOR TREATING ONYCHOMYCOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996036311-A1 | USE OF GLYCERYL TRIACETATE FOR TREATING ONYCHOMYCOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-11-21 | — | — | WO | disclosed |
| EP-0241918-B1 | 1-HYDROXY-2-PYRIDINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM, AS WELL AS INTERMEDIATES FORMED BY THE PREPARATION OF 1-HYDROXY-2-PYRIDINONES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-27 | — | — | EP | disclosed |
| US-4797409-A | FUNGICIDES, YEAST INFECTIONS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-10 | — | — | US | disclosed |
| EP-0241918-A2 | 1-Hydroxy-2-pyridinones, process for their preparation and medicines containing them, as well as intermediates formed by the preparation of 1-hydroxy-2-pyridinones | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112153-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | CYP24A1, CYP27B1, HSD3B1 | IDH1 1238/4885 |
| US-20070071705-A1 | Topical anti-microbial compositions | CUTA, LSS, LIPA | IDH1 4708/4885 |
| US-20100076031-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | CYP24A1, CYP27B1, HSD3B1 | IDH1 1238/4885 |
| US-20120329835-A1 | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | CYP24A1, CYP27B1, HSD3B1 | IDH1 1427/4885 |
| US-20110269801-A1 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | CYP24A1, CYP27B1, HSD3B1 | IDH1 1238/4885 |
| US-20110112150-A2 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS | CYP24A1, CYP27B1, HSD3B1 | IDH1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.